Classification and treatment of tardive syndromes

Neurologist

Volumn 9, Issue 1, 2003, Pages 16-27

  Fernandez, Hubert H ^a,b   Friedman, Joseph H ^a  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Akathisia; Dystonia; Neuroleptic; Tardive dyskinesia; Tardive syndromes

Indexed keywords

AMOXAPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CINNARIZINE; CLEBOPRIDE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUNARIZINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; METOCLOPRAMIDE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; REMOXIPRIDE; RESERPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG;

AKATHISIA; ARM; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSTONIA; FACE INJURY; HUMAN; INVOLUNTARY MOVEMENT; META ANALYSIS; MOTOR DYSFUNCTION; MYOCLONUS; NECK INJURY; NERVOUSNESS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; RESTLESSNESS; REVIEW; TARDIVE DYSKINESIA; TIC; TREMOR; TRUNK;

AKATHISIA, DRUG-INDUCED; DOPAMINE ANTAGONISTS; HUMANS; MOVEMENT DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 0037254622     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000038585.58012.97     Document Type: Review

References (147)

1. Fahn S. Tardive dyskinesias. In: Matthews WB, Glaser GH, eds. Recent Advances in Clinical Neurology, Vol 4. Edinburgh: Churchill Livingstone; 1984:229-260.
2. Stacy M, Jankovic J. Tardive dyskinesia. Curr Opin Neurol Neurosurg. 1991;4:343-349.
3. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry. 1980;137:1163-1172.
4. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156:309-311.
5. Fenn DS, Moussaoui D, Hoffman WF, et al. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology. 1996;123:206-210.
6. Fenton WS, Blyler CR, Wyatt RJ, et al. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry. 1997;171:265-268.
7. Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992;7:62-63.
8. LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord. 1993;8:331-334.
9. Hitri A, Weiner W, Borison R, et al. Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol. 1978;3:134-140.
10. Klawans HL, Tanner CM, Goetz CG. Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol. 1988;49:185-97.
11. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry Res. 1991;40:157-166.
12. Tsai G, Goff DC, Chang RW, et al. Markers of glutamitergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998;155:1207-1213.
13. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry. 1991;48:1097-1106.
14. Schonecker VM. Ein eigentumliches Syndrom im oralem Bereich bei Megaphenapplikation. Nervenarzt. 1957;28:35-43.
15. Sigwald J, Bouttier D, Raymondeaud C, et al. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par less neuroleptiques. Revue Neurologique. 1959;100:751-755.
16. Faurbye A, Rasch PJ, Peterson PB, et al. Neurological symptoms in pharmacotherapy ofpsychoses. Acta Psychiatrica Scand. 1964;40:10-27.
17. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197-214.
18. Yassa R, Lai S. Respiratory irregularity and tardive dyskinesia. Acta Psychiatr Scand. 1986;73:506-510.
19. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22:254-258.
20. Barnes TRE, Kidger T, Gore SM. Tardive dyskinesia: a 3-year follow-up study. Psychol Med. 1983;13:71-81.
21. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol, 1988;8:525-565.
22. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994;151:836-841.
23. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors. Arch Gen Psychiatry. 1982;39:473-481.
24. Muscettola G, Pampallona S, Barbato G, et al. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993;87:29-36.
25. Jeste DV, Caliguiri MP. Tardive dyskinesia (review). Schizophrenia Bull. 1993;19:303-315.
26. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000; 61(suppl 4):27-32.
27. Wegner J, Kane J. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry. 1982;139:368-369.
28. Klawans HL, Tanner DM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol. 1984;7:153-159.
29. Casey DE, Povlsen UJ, Meidahl B, et al. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years ofcontinuing treatment. Psychopharmacol Bull. 1986;22:250-253.
30. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985;34:211-219.
31. Gardos G, Cole JO, Haskell D, et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol. 1988;8:31-37.
32. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001;56:805-807.
33. Druckman R, Seelinger D, Thulin B. Chronic involuntary movements induced by phenothiazines. J Nerv Ment Dis. 1962;135:69-76.
34. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335-1346.
35. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord. 1986;1:193-208.
36. Fitzgerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989; 39:1434-1437.
37. Tan CH, Chiang PC, Ng LL, et al. Oculogyric spasm in Asian psychiatric inpatients on maintenance medication. Br J Psychiatry. 1994; 165:381-383.
38. Micheli F, Pardal MF, Gatton M, et al. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol. 1993;16:315-323.
39. Sethi KD, Hess DC, Hannon D. Reverse obstructive sleep apnea syndrome. Neurology. 1988;38:312.
40. Yassa R, Nair V Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand. 1986;73:629-633.
41. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry. 1987;50:801-803.
42. Sachdev P. Prevalence of tardive dystonia in patients with chronic schizophrenia. Aust N Z J Psychiatry. 1991;25:446-448.
43. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord. 1990;5:319-321.
44. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993;43:937-941.
45. Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. Brain. 1998;121:2053-2066.
46. Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975; 16:43-47.
47. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry. 1985;42:874-878.
48. Gibb WRG, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry. 1986;157:585-592.
49. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157-175.
50. Tarsy D. Akathisia. In: Joseph AB, Young RR, eds. Movement Disorders in Neurology and Psychiatry. 2nd ed. Boston: Blackwell; 1999:75-83.
51. Schilkurt VR, Duran E, Haverback C, et al. Verlauf von psychopathologischen und extrapysrmidalmotorischen symptomen unter einer Langzeit-Neurolepticka bahndlung schizophrener Patienten. Drug Res. 1978;28:1484-1495.
52. Stahl S. Tardive Tourette syndrome in autistic patients after long term neuroleptic administration. Am J Psychiatry. 1980;137:1267-1269.
53. Muller J, Aminoff MJ. Tourette like syndrome after long term neuroleptic drug treatment. Br J Psychiatry. 1982;141:191-193.
54. Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord. 1995;10:791-793.
55. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus. Lancet. 1987;1:322.
56. Stacy MS, Jankovic J. Tardive tremor. Mov Disord. 1992;7:53-57.
57. Marsalek M. Tardive-induced extrapyramidal syndromes. Pharmacopsychiatry, 2000;33(suppl 1):14-33.
58. Polizos P, Engelhardt DM, Hoffman SP, et al. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr. 1973;3:247-253.
59. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry. 2000;61(suppl 4):39-44.
60. Raja M, Maisto G, Altavista MC, et al. Tardive lingual dystonia treated with clozapine. Mov Disord. 1996;11:585-586.
61. Van Harten PN, Kampuis DJ, Matroos GE. Use ofclozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:263-274.
62. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997;58:318-322.
63. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 1997;12:483-496.
64. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54:327-330.
65. Gerlach J, Koppelhus P, Helwez E. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50:410-424.
66. Simpson G, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesias. Psychopharmacology. 1978;56:75-80.
67. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movements disorders. Am J Psychiatry. 1979; 136:317-320.
68. Lieberman JA, Saltz BL, John CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-510.
69. Small JG, Milstein V, Markenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis. J Clin Psychiatry. 1987;48:263-267.
70. Cole JO, Gardos G, Tarsy D, et al. Drug trials in persistent dyskinesia. In: Fahn WE, Smith RC, Davis JM, eds. Tardive Dyskinesia, Research and Treatment. New York: SP Medical and Scientific Books; 1980:419-427.
71. Gerbino L, Shopsin B, Collra M. Clozapine in the treatment oftardive dyskinesias: an interim report. In: Fahn WE, Smith RC, Davis JM, eds. Tardive Dyskinesia, Research and Treatment. New York: SP Medical and Scientific Books; 1980:475-489.
72. Kane JM, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
73. Wilson WH. Clinical review of clozapine treatment in a state psychiatric hospital. Hosp Commun Psychiatry. 1992;43:700-703.
74. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Ment Health Serv. 1993;31:14-18.
75. Gerlach J, Peacock L. Motor and mental side effects of clozapiiie. J Clin Psychiatry. 1994;55:107-109.
76. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal models. J Clin Psychiatry. 1994;55:102-106.
77. Fernandez HH, Friedman JH. The role of a typical antipsychotics in the treatment of movement disorders. CNS Drugs 1999;11:467-483.
78. Meltzer HY, Luchins DL. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol. 1984;4:286-287.
79. Van Putten T, Wirshing WS, Marder SR. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol. 1990;10:381-382.
80. Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: a case report and hypotheses. Mov Disord. 1994;9:441-446.
81. Friedman JH. Clozapine treatement of psychosis in patients with tardive dystonia: report of three cases. Mov Disord. 1994;9:321-324.
82. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J New Ment Dis. 1993;181:137-138.
83. Blake LM, Marks RC, Nierman P, et al. Clozapine and clonazepam in tardive dystonia. J Clin Psychopharmacol. 1991;11:268-269.
84. Friedman JH. Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naïve patient induced by risperidone. Med Health. 1998;81:271-272.
85. Campbell M. Risperidone-induced tardive dyskinesia in first-episode psychotic patients. J Clin Psychopharmacol. 1999;19:276-277.
86. Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry. 1995;56:484-485.
87. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone? Am J Psychiatry. 1996;153:843-844.
88. Gwinn KA, Caviness JN. Resperidone-induced tardive dyskinesia and parkinsonism. Movement Disord. 1997;12:119-121.
89. Vercueil L, Foucher J. Risperidone-induced tardive dystonia and psychosis. Lancet. 1999;353:981-982.
90. Ipekei S, Birsoz S. Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine. Eur Psychiatry. 2001;16:259-260.
91. Mullen A. Risperidone and tardive dyskinesia: a case of blepharospasm. Aust N Z J Psychiatry. 2000;34:879-880.
92. Snoddgrass PL, Labbate LA. Tardive dyskinesia from risperidone and olanzapine in an alcoholic man. Can J Psychiatry. 1999;44:921.
93. Lemmens P, Brecher M, Van Baelen B. A combined analysis ofdouble blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999;99:160-170.
94. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
95. Tarsy D, Baldessarini RJ, Taraz FI. Effects of Newer antipsychotics on extrapyramidal function. CNS Drugs. 2001;16:23-45.
96. Esel E, Turan MT, Sofuoglu S, et al, Improvement of tardive dyskinesia in a bipolar patient with olanzapine. Eur Psychiatry. 2000; 15:438-439.
97. Raja M, Azzoni A, Maisto G. Three cases of improvement of tardive dyskinesia following olanzapine treatment. Int J Neuropsychopharmacol. 1999;2:333-334.
98. Haberfellner EM. Remission of tardive dyskinesia after changing from flupenthixol to olanzapine. Eur Psychiatry. 2000;15:338-339.
99. Khan M, Farver D. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine. S D J Med. 2000;53:65-67.
100. Lykouras L, Malliori M, Christodoulou GN. Improvement of tardive dyskinesia following treatment with olanzapine. Eur Neuropsychopharmacol. 1999;9:367-368.
101. Soutullo CA, Keck PE Jr, McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol. 1999; 19:100-101.
102. Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry. 1998;59:380-381.
103. O'Brien J, Barber R. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br J Psychiatry. 1998;172:186.
104. Littrell KH, Johnson CG, Littrell S, et al. Marked reduction oftardive dyskinesia with olanzapine. Arch Gen Psychiatry. 1998;55:279-280.
105. Tollefson GD, Beasely CM, Tamur RN, et al. Blind, controlled long term study of comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154:1248-1254.
106. Dunayevitch E, Strakowski SM. Olanzapine induced tardive dystonia. Am J Psychiatry. 1999;156:1662-1663.
107. Herrran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine. Ann Intern Med. 1999;131:72-73.
108. Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry. 1999;60:870.
109. Kinon BJ, Basson BR, Stauffer VL, et al. Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia. Presented at the 37th meeting of the American College of Neuropsychopharmacology, January 14-18, 1998; San Juan, PR.
110. Glazer WM, Morgenstem H, Pultz JA, et al. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. Neurology. 2000;54(suppl 3):A51-A52.
111. Doepp S, Buddeberg C. Extrapyramidale symptome unter Clozapine. Nervenarzt. 1975;46:589-590.
112. De Leon J, Moral L, Camunas C. Clozapine and jaw dyskinesia: case report. J Clin Psychiatry. 1991;52:494-495.
113. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry. 1994; 35:886-887.
114. Peacock L, Solgaard T, Lublin H, et al. Clozapine vs typical antipsychotics: a retro-and prospective study of extrapyramidal side effects. Psychopharmacology. 1996;124:188-196.
115. Modestin J, Stephan PL, Emi T, et al. Problems of extrapyramidal syndromes in psychiatric inpatients and relationship of clozapien treatment to tardive dyskinesia. Schizophren Res. 1000;42:223-230.
116. Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord. 1999;14:873-874.
117. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789-794.
118. Huang CC, Wang RIH, Hasegawa A, et al. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology. 1981;73:359-362.
119. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: 2 decades of experience. Arch Gen Psychiatry. 1982;39:803-816.
120. Kazamarsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. Arch Gen Psychiatry. 1972;27:95-99.
121. Godwin-Austern RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J. 1971:2:25-26.
122. Jankovic J, Beach J. Long-term effects of tetrabenzine in hyperkinetic movement disorders. Neurology. 1997;48:358-362.
123. Tarsy D. Tardive dyskinesia. Curr Treatment Options Neurol. 2000;2:205-213.
124. Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol. 1985;17:200-202.
125. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445-451.
126. McGrath JJ, Soares KVS. Benzodiazepines for neuroleptic-induced tardvie dyskinesia (Cochrane Review). In: The Cochrane Library. Issue 4. Oxford: Update Software; 2001.
127. Adler LA, Pesalow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150:1403-1407.
128. Dabiri LM, Pasta D, Darby JK, et al. Effectiveness of vitamin E for the treatment of long-term tardive dyskinesia. Am J Psychiatry. 1994;159:925-926.
129. Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia. Lancet. 1987;1:913-14.
130. Eagen MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 1992;149:773-777.
131. Shriqui CL, Bradwejn J, Annabel L, et al. Vitamin E and the treatment of tardive dyskinesia: a double blind placebo-controlled study. Am J Psychiatry. 1992;149:391-393.
132. Dorevitch A, Kallian M, Shlafman M, et al. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry. 1997;41:114-116.
133. Soares KVS, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia (Cochrane Review). In: The Cochrane Library. Issue 4. Oxford: Update Software; 2001.
134. Suzuki T, Hori T Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (Pisa syndrome). J Clin Psychopharmacol. 1999;19:277-280.
135. Stewart RM, Rollins J, Beckham B, et al. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol. 1982;5:365-373.
136. Duncan E, Adler L, Angrist B, et al. Nifedipine in the treatment of tardive dyskinesia. J Clin Pharmacol. 1990;10:414-416.
137. Cowen MA, Green M, Bertollo DN, et al. A treatment of tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol. 1997;17:190-193.
138. Weetman J, Anderson JM, Gregow RP, et al. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry. 1997;63:554-556.
139. Hillier CE Wiles CM, Simpson BA. Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry. 1999;66:250-251.
140. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol. 1997;20:90-93.
141. Brashear A, Ambrosius WT, Eckert GJ, et al. Comparison treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin A. Mov Disord. 1998;13:158-161.
142. Chatterjee A, Gordon MF. Giladi N, et al. Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol. 1997;17:497-498.
143. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord. 1998;13:552-555.
144. Kanovsky P, Streitova H, Bares M, et al. Treatment of facial and orolingualmandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord. 1999;14:886-888.
145. Dressler D, Oeljesschlager RO, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord. 1997;12:585-857.
146. Hermesh H, Aizenberg D, Freidberg G, et al. Electroconvulsive therapy for persistent neuroleptic-induced akathisia and parkinsonism: a case report. Biol Psychiatry. 1992;31:407-441.
147. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999;14:484-487.